{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T10:59:55Z","timestamp":1794481195716,"version":"4.9.1"},"reference-count":19,"publisher":"American Society for Microbiology","issue":"5","license":[{"start":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T00:00:00Z","timestamp":1714608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T00:00:00Z","timestamp":1714608000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100017467","name":"Amplyx","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017467","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2024,5,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Fosmanogepix [FMGX, APX001; active form: manogepix (MGX), APX001A] is a first-in-class, intravenous (IV)\/oral antifungal currently being evaluated for invasive fungal disease treatment. Data from two phase 1, placebo-controlled studies [IV\u2013oral switch (study 1) and multiple IV doses (study 2)] evaluating FMGX tolerability, and pharmacokinetics (PK) are presented. Healthy adults (study 1: 18\u201365 years; study 2: 18\u201355 years) were eligible (randomized 3:1 to FMGX: placebo). Eleven participants completed study 1. In study 2, 51 participants (48 planned + 3 replacement) were enrolled in six cohorts (8 participants each; 34 completed the study). In study 1, overall MGX systemic exposures were comparable from day 1 to day 42 of dosing; steady-state plasma concentrations were achieved in \u226424 h following two IV loading doses (1,000 mg) and exposures maintained after switching [IV (600 mg) to daily oral doses (800 mg)]. FMGX was safe and well-tolerated. In study 2, FMGX IV doses (loading doses twice daily\/maintenance doses once daily; 3-h infusion) of 1,500\/900 mg (cohort A), 900\/900 mg (cohort B), and 1,000\/900 mg (cohort C: with ondansetron) were not well-tolerated; most participants reported nausea and infrequent vomiting. FMGX IV doses of 1,000\/750 mg (cohort D), 1,000\/850 mg (cohort E), and 1,000\/900 mg (cohort F: ondansetron prn) were relatively better tolerated. Steady-state systemic exposures were achieved between days 2 and 4. All cohorts had similar geometric mean (GM) concentrations during maintenance dosing and similar GM PK parameters. Dosing regimen evaluated in study 1 was safe, well-tolerated, and may be used for future clinical evaluations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1128\/aac.01455-23","type":"journal-article","created":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T09:00:27Z","timestamp":1711702827000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":13,"title":["Pharmacokinetics, safety, and tolerability of fosmanogepix IV to oral switch and multiple IV doses in healthy participants"],"prefix":"10.1128","volume":"68","author":[{"given":"Michael R.","family":"Hodges","sequence":"first","affiliation":[{"name":"Amplyx Pharmaceuticals, Inc., San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Hazel","sequence":"additional","affiliation":[{"name":"Amplyx Pharmaceuticals, Inc., San Diego, California, USA"},{"name":"Pfizer Inc., New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William G.","family":"Kramer","sequence":"additional","affiliation":[{"name":"Kramer Consulting LLC, North Potomac, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewoud-Jan","family":"van Hoogdalem","sequence":"additional","affiliation":[{"name":"ICON, Groningen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sjoerd","family":"van Marle","sequence":"additional","affiliation":[{"name":"ICON, Groningen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6815-2647","authenticated-orcid":true,"given":"Margaret","family":"Tawadrous","sequence":"additional","affiliation":[{"name":"Pfizer Inc., New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2196-5782","authenticated-orcid":true,"given":"Abhijeet","family":"Jakate","sequence":"additional","affiliation":[{"name":"Pfizer Inc., New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3004404"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/mmy\/myz012"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.3390\/jof6040239"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00731-11"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix130"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01611-0"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00291-11"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00366-11"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01623-22"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx163.1390"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx163.1370"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01419-22"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab1070"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ933"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw326"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx446"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa439.1343"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa439.457"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.281053"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01455-23","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01455-23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T09:01:41Z","timestamp":1714640501000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.01455-23"}},"subtitle":[],"editor":[{"given":"Andreas H.","family":"Groll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,5,2]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5,2]]}},"alternative-id":["10.1128\/aac.01455-23"],"URL":"https:\/\/doi.org\/10.1128\/aac.01455-23","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,2]]},"assertion":[{"value":"2023-11-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01455-23"}}